inosine-pranobex and Carcinoma--Small-Cell

The comparative studies presented in this work aimed at evaluation of isoprinosine in the combined cytostatic and irradiation treatment of small cell lung cancer. The comparison was performed between three groups of patients: 1. treated by the method of Livingston et al., 2. treated by the method of Livingston et al. in a combination with isoprinosine, 3. treated by the same method but the cycle of treatment was shortened from 3 weeks to 8 days with the parallel application of isoprinosine as immunotherapeutic and stimulator of the hematopoietic system. It was found that the mean time of complete and partial remission and the mean survival time was longer in the second and third group of patients. The mean survival time in the first group amounted to 3 weeks, in the second to 43 weeks and in the third to 49 weeks. It was also shown that post-chemotherapy complications were less frequent and less intensive.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Inosine Pranobex; Lung Neoplasms; Male; Middle Aged

An immunologic study was undertaken on 89 lung cancer patients and on the basis of results obtained so far, a protocol of active, aspecific immunotherapy by living bacterial vaccines (BCG) and/or synthetic immunopotentiator (methisoprinol) was carried out. First results obtained in patients undergoing immunostimulation are reported together with the observation that while positive humoral effects seem present in stage I and II patients, in cases of spread of the disease results are substantially negative.

Topics: Adenocarcinoma; Adult; BCG Vaccine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Humans; Immunoglobulins; Immunotherapy; Inosine; Inosine Pranobex; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Rosette Formation